Aug 17 2017
RiaSTAP
Although the FDA approved CSL-Behring’s RiaSTAP, human plasma-derived fibrinogen concentrate in 2009, it seems most facilities continue to use cryoprecipitate to treat hypofibinogenemia, dysfibrinogenemia, and afibrinogenemia. Has your institution switched to RiaSTAP? Why, or why not? For the answer, see this reference provided by George’s UAB colleague, pathologist Lawrence A. Williams III: “After adjusting for […]
read more